PHARMACEUTICAL RESEARCH

药学研究共享资源 大卫亚当斯，博士，阿什利莫里斯-恩格曼，药学博士，联合导演 药物研究共享资源包括研究性化疗服务和Cancex 临床药理学实验室，提供广泛的服务，以支持进行临床 血液学/本体学研究。研究性化疗服务（ICS）适用于所有癌症中心 研究者为了维护药物验收记录和研究药物库存， FDA和CTEP指南。此外，该资源还提供设计咨询，专业人员教育， 临床研究的实施服务。临床药理学实验室（CPL）的主要重点是 研究抗癌药物和重组蛋白的药代动力学和药效学， 癌症的实验性治疗该资源也可用于分析内源性细胞因子浓度 在研究治疗期间。该实验室的主要目标之一是确定反应的预测因子， 毒性和实施方法以减少药物暴露患者间差异。该实验室提供咨询服务， 以及有关抗癌化合物和重组蛋白的临床药代动力学研究的分析服务。 这些包括：试验设计辅助、最佳取样技术、样品处理和稳定性、定量 药物和代谢物浓度的测量（通过HPLC、原子吸收分光光度法、气相色谱法） 色谱法/质谱法或ELISA），计算个体和群体药代动力学 通过复杂的计算机建模程序进行参数和药理学评价。此资源 癌症中心研究人员（包括实验治疗公司的研究人员）保持了高水平的使用率 计划，乳腺和卵巢骨髓放射和 本体论，移植，神经肿瘤学，肿瘤学 热疗和癌症免疫学项目。在上一个财政年度，100%的资源利用率是 为同行评审的研究者生成。

PHARMACEUTICAL RESEARCH SHARED RESOURCE David Adams, Ph.D., Ashley Morris-Engemann, Pharm.D., Co-Directors The Pharmaceutical Research Shared Resource consists of an lnvestigational Chemotherapy Service and a Cancex Clinical Pharmacology Laboratory, provides a broad range of services to support the conduct of clinical hematology/ontology research. The Investigational Chemotherapy Service (ICS) is available to all Cancer Center investigators for the purpose of maintaining drug accotmtability records and investigafional drug inventories according to FDA and CTEP guidelines. In addition, this resource provides design consultation, professional staff education, and implementation services for clinical research studies. The primary focus of the Clinical Pharmacology Lab (CPL) is to investigate the pharmacokinetics and pharmacodynamics of anticancer drugs and recombinant proteins used in the experimental therapy of cancer. This resource is also available for analysis of endogenous cytokine concentrations during investigational therapy. One of the major goals of the laboratory is to identify predictors of response and toxicity and implement methods to reduce inter-patient variability of drug exposure. The lab provides both consultative and analytic services regarding clinical pharmacokinetie studies of anticancer compounds and recombinant proteins. These include: aid with trial design, optimal sampling techniques, sample handling and stability, quantitative measurement of drug and metabolite concentrations (via HPLC, atomic absorption spcetrophotometry, gas chromatography/mass spectrophotometry, or ELISA), calculation of individual and population pharmacokinetic parameters and pharmacometric evaluation via sophisticated computer modeling programs. This resource has maintained a high level of usage by Cancer Center investigators including those from the Experimental Therapeutics Program, Breast and Ovarian Bone Marrow Radiation and Ontology, Transplantation, Neuro-Oncology, Oncology Hyperthermia, and Cancer Immtmobiology Programs. During the last fiscal year, 100% of the resource utilization was generated for peer-reviewed investigators.